(Q33303421)

25 July 2017

1 reference

title

Molecules that target beta-amyloid (English)

1 reference

25 July 2017

Cliff I Stains

1

1 reference

25 July 2017

Kalyani Mondal

series ordinal

2

1 reference

25 July 2017

Indraneel Ghosh

series ordinal

3

1 reference

25 July 2017

publication date

1 December 2007

1 reference

25 July 2017

1 reference

25 July 2017

volume

2

1 reference

25 July 2017

issue

12

1 reference

25 July 2017

page(s)

1674-1692

1 reference

The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

On the histochemistry of azo group-free thiazole dyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

Pathological and functional amyloid formation orchestrated by the secretory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloid diseases: abnormal protein aggregation in neurodegeneration

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Purification and characterization of the human gamma-secretase complex

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Notch and the amyloid precursor protein are cleaved by similar gamma-secretase(s).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloid fibrillogenesis: themes and variations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Protein folding and misfolding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Pathologic conformations of prion proteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Observation of metastable Abeta amyloid protofibrils by atomic force microscopy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Diseases of unstable repeat expansion: mechanisms and common principles

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

The HPV16 E7 viral oncoprotein self-assembles into defined spherical oligomers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

The small heat-shock protein, alphaB-crystallin, has a variable quaternary structure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Single-site mutations in a hyperthermophilic variant of the B1 domain of protein G result in self-assembled oligomers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Self-assembly properties of recombinant engineered amelogenin proteins analyzed by dynamic light scattering and atomic force microscopy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Molecular structure of amyloid fibrils: insights from solid-state NMR.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Abeta40-Lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Neurodegenerative disease: amyloid pores from pathogenic mutations.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

A specific amyloid-beta protein assembly in the brain impairs memory

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Identification of small-molecule inhibitors of the Abeta-ABAD interaction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloid beta-protein stimulates casein kinase I and casein kinase II activities.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloid beta peptide binds a novel death-inducing protein, AB-DIP.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Binding of gelsolin, a secretory protein, to amyloid beta-protein

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Interaction of beta-amyloid peptides with integrins in a human nerve cell line

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Physiological levels of beta-amyloid peptide stimulate protein kinase C in PC12 cells.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Transthyretin sequesters amyloid beta protein and prevents amyloid formation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

A novel peptide prevents death in enriched neuronal cultures.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Kinetics of inhibition of beta-amyloid aggregation by transthyretin.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Arrest of beta-amyloid fibril formation by a pentapeptide ligand

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Affinity-Based Inhibition of β-Amyloid Toxicity†

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Beta-amyloid-derived pentapeptide RIIGLa inhibits Abeta(1-42) aggregation and toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Stoichiometric inhibition of amyloid beta-protein aggregation with peptides containing alternating alpha,alpha-disubstituted amino acids

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Probing the role of backbone hydrogen bonding in beta-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Inhibitors of fibril formation and cytotoxicity of beta-amyloid peptide composed of KLVFF recognition element and flexible hydrophilic disrupting element.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Modified-peptide inhibitors of amyloid beta-peptide polymerization

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Targeted control of kinetics of beta-amyloid self-association by surface tension-modifying peptides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Design strategies for anti-amyloid agents.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Set back to Alzheimer vaccine studies.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Conformational Abs recognizing a generic amyloid fibril epitope

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Engineered proteins as specific binding reagents.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Dual surface selection methodology for the identification of thrombin binding epitopes from hotspot biased phage-display libraries

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Identification of peptides that specifically bind Abeta1-40 amyloid in vitro and amyloid plaques in Alzheimer's disease brain using phage display

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Phage display affords peptides that modulate beta-amyloid aggregation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Inhibition of beta-amyloid fibrillization by directed evolution of a beta-sheet presenting miniature protein

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Identification of D-peptide ligands through mirror-image phage display

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Design, structure and stability of a hyperthermophilic protein variant

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Stimulatory and inhibitory effects of alkyl bromide surfactants on beta-amyloid fibrillogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Metal complexing agents as therapies for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

New Class of Inhibitors of Amyloid-beta Fibril Formation. IMPLICATIONS FOR THE MECHANISM OF PATHOGENESIS IN ALZHEIMER'S DISEASE

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Is Congo red an amyloid-specific dye?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Synthesis and evaluation of two 18F-labeled 6-iodo-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Amyloid binding ligands as Alzheimer's disease therapies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Mechanism of A beta(1-40) fibril-induced fluorescence of (trans,trans)-1-bromo-2,5-bis(4-hydroxystyryl)benzene (K114).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

A novel compound RS-0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Controlling {beta}-amyloid oligomerization by the use of naphthalene sulfonates: trapping low molecular weight oligomeric species

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Correlation between major histocompatibility complex class I molecules and CD8+ T lymphocytes in prostate, and quantification of CD8 and interferon-gamma mRNA in prostate tissue specimens

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Rapid protein-folding assay using green fluorescent protein

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Peptide and amide bond-containing dendrimers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Helical supramolecules and fibers utilizing leucine zipper-displaying dendrimers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700140

7 January 2021

Identifiers

DOI

10.1002/CMDC.200700140

1 reference

25 July 2017

1 reference